Clinical Trial Update: Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial results for NCP-5 in mild cognitive impairment due to Alzheimer’s disease or mild dementia of the Alzheimer’s type have been completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia of the Alzheimer Type

Drugs mentioned

• NCP-5

Snippet

Sponsor: Renew Research, LLC | Conditions: Alzheimer Disease, Cognitive Dysfunction | Phase 3 | Status: COMPLETED | Results posted: 2022-04-19